A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://www.
Cerus now has exclusive rights to the INTERCEPT Blood System for all three commonly transfused components: platelets, plasma and red blood cells, excluding rights in certain Asian countries for platelets and plasma.
Cerus and Baxter Healthcare Corporation are collaborating on the development of INTERCEPT Blood System to enhance the safety of blood transfusions.
chairman and chief executive officer of Baxter said, "We are very pleased with the significant progress of the Cerus and Baxter teams.
This financing significantly strengthens our balance sheet and provides additional resources to fund our research and development programs," said Stephen Isaacs, Cerus president and chief executive officer.
CONTACT: Lisa Luttinger of Cerus Corporation, +1-925-288-6036
Baxter and Cerus expect to be the first to file for regulatory approval of a pathogen inactivation system for platelets," stated Harry M.
To access the live webcast, please visit the Investor Relations page of the Cerus website at http://www.
Cerus Corporation is developing medical systems and therapeutics to provide safer and more effective options to patients.
We are honored that Swiss Red Cross centers in Zurich and Lausanne have chosen INTERCEPT as their pathogen inactivation technology for plasma," said Caspar Hogeboom, president of Cerus Europe.
Cerus Corporation is building on its leading position in the biopharmaceutical industry by developing medical systems and therapeutics to provide safer and more effective options to patients.
What: Cerus Corporation's Third Quarter Earnings Conference Call